Basic Science Review
This is the first in a series of periodic reviews of the scientific literature that the Basic Science Project will be making available via the TAG website. September 2002 Exploding CD4 T Cell Counts STIs in Chronic Infection: Predicting Success…
2002 Keystone Conference Updates
by Richard Jeffreys May 2002 Every year, Keystone Symposia sponsor two parallel conferences on HIV pathogenesis and vaccines. The meetings take place at the Keystone Resort high in the Rocky Mountains, allowing researchers to mix the latest data with a…
What’s in Glaxo’s HIV Vaccine?
March 1, 2002 "The first human trial with GlaxoSmithKline Biologicals' (GSK Biologicals) candidate HIV vaccine will test whether the vaccine, which prevented AIDS in rhesus monkeys, is safe and immunogenic in humans." -- GlaxoSmithKline Biologicals Press Release, Jan 31, 2002…
Report from the 3rd International STI Workshop, 2002
March 23-24, 2002 Montréal, Quebec, Canada Sponsored by: Foundation for AIDS & Immune Research The Forum for Collaborative HIV Research Gay Men's Health Crisis Project Inform Treatment Action Group Linda Grinberg (1951–2002) · In Memoriam Linda Grinberg, a fearless AIDS…
Comments on Problems in the Current Draft World Health Organization (WHO) Antiretroviral Treatment Guidelines for Resource Limited Settings
By Mark Harrington March 2002 Twenty-one years into the HIV pandemic the World Health Organization (WHO) has loosened itself from its slothlike lethargy and bureaucratic torpor to produce, seemingly with great reluctance and certainly with great confusion, a draft document…
The Promise of New Vaccine Vectors, the Perils of Partial Protection
Two New HIV Vaccine Studies Published In the Journal Nature By Richard Jeffreys March 1, 2002 January 2002 proved to be a month of mixed blessings for the AIDS vaccine field. A slew of new papers in the prestigious journal…
To Double, or Not to Double?
Bioterror Buys a Budget Boost By Mark Harrington February 2002 Ten years ago, TAG was one of the only voices calling for the nation to double its investment in biomedical research at the National Institutes of Health (NIH). We felt…
Position Paper on NDA 21-356 for Gilead Sciences’ Viread brand Tenofovir disoproxil fumarate
By Yvette Delph, MD October 3, 2001 1. INTRODUCTION In May 2001, Gilead Sciences submitted New Drug Application (NDA) 21-356 to the FDA for its VireadTM brand of tenofovir disoproxil fumarate (TDF). Gilead is seeking accelerated approval for TDF to…